Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INO-5401 + cemiplimab
- Development stage
- Unknown
- Lead developer
- Inovio Pharmaceuticals
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
INO-5401 + Libtayo is a combination immunotherapy regimen consisting of INO-5401, a synthetic DNA medicine, and cemiplimab (Libtayo), a programmed death receptor-1 (PD-1) blocking monoclonal antibody. INO-5401 is designed to activate the immune system against multiple tumor-associated antigens, including human telomerase reverse transcriptase (hTERT), Wilms tumor gene 1 (WT1), and prostate-specific membrane antigen (PSMA). Cemiplimab acts as a checkpoint inhibitor to prevent the PD-1/PD-L1 interaction, thereby enhancing T-cell mediated anti-tumor responses. This combination is primarily being investigated for the treatment of newly diagnosed glioblastoma (GBM) to improve survival outcomes by priming and sustaining a robust immune response against the tumor. The regimen often includes INO-9012, a DNA plasmid encoding interleukin-12 (IL-12), which serves as an immune booster.
- Other names
- INO-5401 + LibtayoINO-5401 + cemiplimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PSMA (Prostate-specific membrane antigen)TERT (Telomerase)WT1 (Wilms tumor protein)BRCA1 (Breast cancer type 1 susceptibility protein)FAD (Flavin adenine dinucleotide)
Beyond the preview
Go deeper on INO-5401 + cemiplimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INO-5401 + cemiplimab.